Seventh Sense Biosystems appoints Weisman as president and CEO

Thursday, June 14, 2012 12:21 PM

Seventh Sense Biosystems, a Cambridge, Mass.-based privately-held medical device company developing the novel Touch Activated Phlebotomy (TAP) painless blood sampling system, has appointed Howard Weisman as president, CEO and board member.  

Weisman comes to Seventh Sense with experience launching medical products, most recently as the founder, chairman, and CEO of EKR Therapeutics, which announced its sale to Cornerstone Therapeutics in May 2012.  Prior to his role at EKR, Weisman co-founded ESP Pharma, serving as its president and COO from its initial funding in 2001 through to its sale to PDL BioPharma in 2005 for over $500 million.  He began his career in sales and marketing at Merck and later joined Parke Davis, a division of Warner Lambert, to oversee the launch of its diabetes franchise in 1995.

The company also announced that it has closed the final tranche of a $10 million series A financing with existing investors Flagship Ventures and Polaris Venture Partners.  The company will use this financing to complete clinical testing and to commercialize its first TAP-based blood collection device for point of care diagnostics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs